Page 8 - CUAJ Dec. 2022
P. 8
CHOOSE XTANDI.
mCSPC mCRPC nmCRPC
Pr XTANDI® (enzalutamide XTANDI is indicated in the setting XTANDI is indicated for the treatment
capsules) is indicated of medical or surgical castration of patients with non-metastatic
for the treatment of for the treatment of metastatic castration-resistant prostate cancer
patients with metastatic castration-resistant prostate (nmCRPC). XTANDI has not been
castration-sensitive prostate cancer (mCRPC) in patients who: studied in patients with nmCRPC
cancer (mCSPC). • are chemotherapy-naïve with at low risk of developing metastatic
asymptomatic or mildly symptomatic disease. The bene
t and risk pro
le
disease after failure in these patients is unknown.
of androgen deprivation therapy.
• have received docetaxel therapy.
LEARN MORE
Please consult the product monograph at https://www.astellas.com/ca/system/
les/xtandi_
pm_jan_24_2022-
nal_en.pdf or call 1-888-338-1824 for important information relating to:
• Contraindications in women who are or may become pregnant, or who are lactating
• The most serious warnings and precautions regarding seizures and Posterior Reversible
Encephalopathy Syndrome (PRES)
• Other relevant warnings and precautions regarding hereditary fructose intolerance,
cytochrome P450 interactions and dose adjustments, carcinogenic potential, cardiovascular
events (including ischemic heart disease, QTc prolongation and hypertension), hypersensitivity
reactions, non-pathological bone fractures or falls and fall-related injuries, neuropsychiatric
adverse events, mental impairment disorders, use of contraception, potential eects on male
fertility, recommendations in severe renal impairment or end-stage renal disease and monitoring
in nmCRPC patients
• Conditions of clinical use, adverse reactions, interactions and dosing
®
©
__
_
MEMBRE DE
23079j_XTANDI_1PgChooseXTANDCUAJ Journal AdEN_REL_C00_00_.indd 1 2022-09-22 2:58 PM
